BioMarin Pharmaceutical Statistics

Total Valuation

BioMarin Pharmaceutical has a market cap or net worth of GBP 9.60 billion. The enterprise value is 9.33 billion.

Market Cap	9.60B
Enterprise Value	9.33B

Important Dates

The next estimated earnings date is Friday, February 21, 2025.

Earnings Date	Feb 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.93%
Shares Change (QoQ)	-1.67%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	179.17M

Valuation Ratios

The trailing PE ratio is 39.91.

PE Ratio	39.91
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	2.60
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.08, with an EV/FCF ratio of 39.10.

EV / Earnings	38.80
EV / Sales	4.17
EV / EBITDA	26.08
EV / EBIT	35.21
EV / FCF	39.10

Financial Position

The company has a current ratio of 4.27, with a Debt / Equity ratio of 0.11.

Current Ratio	4.27
Quick Ratio	2.39
Debt / Equity	0.11
Debt / EBITDA	1.37
Debt / FCF	1.88
Interest Coverage	20.16

Financial Efficiency

Return on equity (ROE) is 6.25% and return on invested capital (ROIC) is 3.40%.

Return on Equity (ROE)	6.25%
Return on Assets (ROA)	3.00%
Return on Capital (ROIC)	3.40%
Revenue Per Employee	603,902
Profits Per Employee	70,703
Employee Count	3,401
Asset Turnover	0.40
Inventory Turnover	1.19

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -32.70% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-32.70%
50-Day Moving Average	65.49
200-Day Moving Average	76.94
Relative Strength Index (RSI)	36.89
Average Volume (20 Days)	1,865

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.94

Income Statement

In the last 12 months, BioMarin Pharmaceutical had revenue of GBP 2.05 billion and earned 240.46 million in profits. Earnings per share was 1.25.

Revenue	2.05B
Gross Profit	1.08B
Operating Income	243.53M
Pretax Income	292.06M
Net Income	240.46M
EBITDA	317.91M
EBIT	243.53M
Earnings Per Share (EPS)	1.25

Full Income Statement

Balance Sheet

The company has 694.20 million in cash and 449.66 million in debt, giving a net cash position of 244.54 million.

Cash & Cash Equivalents	694.20M
Total Debt	449.66M
Net Cash	244.54M
Net Cash Per Share	n/a
Equity (Book Value)	4.04B
Book Value Per Share	21.20
Working Capital	1.75B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 309.41 million and capital expenditures -70.74 million, giving a free cash flow of 238.67 million.

Operating Cash Flow	309.41M
Capital Expenditures	-70.74M
Free Cash Flow	238.67M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 52.35%, with operating and profit margins of 11.86% and 11.71%.

Gross Margin	52.35%
Operating Margin	11.86%
Pretax Margin	14.22%
Profit Margin	11.71%
EBITDA Margin	15.48%
EBIT Margin	11.86%
FCF Margin	11.62%

Dividends & Yields

BioMarin Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.93%
Shareholder Yield	-0.93%
Earnings Yield	2.51%
FCF Yield	2.49%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioMarin Pharmaceutical has an Altman Z-Score of 7.71.

Altman Z-Score	7.71
Piotroski F-Score	n/a